Abstract:Factor XIa, as a blood coagulation enzyme, amplifies the generation of the last enzyme thrombin in the blood coagulation cascade. It was proved that direct inhibition of factor XIa could reduce pathologic thrombus formation without an enhanced risk of bleeding. WSJ-557, a nonpurine imidazole-based xanthine oxidase inhibitor in our previous reports, could delay blood coagulation during its animal experiments, which prompted us to investigate its action mechanism. Subsequently, during the exploration of the action mechanism, it was found that WSJ-557 exhibited weak in vitro factor XIa binding affinity. Under the guide of molecular modeling, we adopted molecular hybridization strategy to develop novel factor XIa inhibitors with WSJ-557 as an initial compound. This led to the identification of the most potent compound 44g with a Ki value of 0.009 μM, which was close to that of BMS-724296 (Ki = 0.0015 μM). Additionally, serine protease selectivity study indicated that compound 44g display a desired selectivity, more 400-fold than those of thrombin, factor VIIa and factor Xa in coagulation cascade. Moreover, enzyme kinetics studies suggested that the representative compound 44g acted as a competitive-type inhibitor for FXIa, and molecular modeling revealed that it could tightly bind to the S1, S1′ and S2′ pockets of factor XIa. Furthermore, in vivo efficacy in the rabbit arteriovenous shunt model suggested that compound 44g demonstrated dose-dependent antithrombotic efficacy. Therefore, these results supported that compound 44g could be a potential and efficacious agent for the treatment of thrombotic diseases.

Study on the synthesis of apixaban

A Novel Asymmetric Synthesis of Cis-(3r, 4R)-N-(tert-butoxycarbonyl)-4-methyl-3-(methylamino) Piperidine

Use of Lipase Catalytic Resolution in the Preparation of Ethyl (2S,5r)-5-((benzyloxy)amino)piperidine-2-carboxylate, a Key Intermediate of the Β-Lactamase Inhibitor Avibactam

Synthesis of 3-Aminopyrrolidine and its N-alkylating Derivatives

Recent Advances in the Synthesis and Analysis of Atorvastatin and Its Intermediates

Synthesis of 6-Fluoro-3,4-dihydro-2h-1-benzopyran-2-carboxylic Acid

Synthesis method of rivaroxaban

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

Development of XIAP Antagonists Based on De Novo 8,5-Fused Bicyclic Lactams.

A method for the synthesis of rivaroxaban

Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment

Synthesis of Intermediate of Rivaroxaban

A Practical Method for Synthesizing Iptacopan

A short and efficient total synthesis of the bromotyrosine-derived alkaloid psammaplysene A

Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues

Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments

The Synthetic Technology of Ranolazine

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Convenient Synthesis and Characterization of Novel 4-[2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzamido]-3-isobutyl-1-methyl-1h-pyrazole-5-carboxamide: Key Precursor for Isobutyl Sildenafil

Circulating Transglutaminase 3-Immunoglobulin A Immune Complexes in Dermatitis Herpetiformis.